Oleg Astafurov, Vice-President of Governmental Affairs, was the speaker on behalf of the Pharmasyntez Group of Companies in the session “Invest into health”. The issues of alternative models of the start-ups financing in current economic situation were discussed in the session.

Development and launch of innovation drugs are strategically important development directions for Pharmasyntez.

The company's portfolio comprises original molecules for the treatment of socially significant diseases in the field of oncology, cardiovascular, and viral diseases.

To maintain and update the portfolio, 3 proprietary R&D centers were opened, works in partnership with leading Russian research centers are being performed. The company is open to dialogue with other companies, including start-ups involved in the development of innovation molecules.

We would like to say special thanks to Skolkovo Fund, particularly to the Cluster of biological and medical technologies, for the development of the projects in the sphere of innovation drugs development.